Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Jae-Yong Kwak

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors

Jae-Yong Kwak

Department of Medicine

Research output: Contribution to journal › Journal article › peer-review

Original language	Korean
Journal	Haematologica
State	Published - 2014.07.4

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{d335052d693e4d6d9bedbe0d6db15842,

title = "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors",

author = "Jae-Yong Kwak",

year = "2014",

month = jul,

day = "4",

language = "Korean",

journal = "Haematologica",

issn = "0390-6078",

}